Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work.
Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.
In 2019, the market size of Angina Pectoris Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Angina Pectoris Drugs.
This report studies the global market size of Angina Pectoris Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Angina Pectoris Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Pfizer
Bayer
AstraZeneca
Gilead
Novartis
GlaxoSmithKline
Merck
Mylan
Teva Pharmaceutical
Market Segment by Product Type
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Market Segment by Application
Hospitals
Clinics
ASCs
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Angina Pectoris Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Angina Pectoris Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Angina Pectoris Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.
In 2019, the market size of Angina Pectoris Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Angina Pectoris Drugs.
This report studies the global market size of Angina Pectoris Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Angina Pectoris Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Pfizer
Bayer
AstraZeneca
Gilead
Novartis
GlaxoSmithKline
Merck
Mylan
Teva Pharmaceutical
Market Segment by Product Type
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Market Segment by Application
Hospitals
Clinics
ASCs
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Angina Pectoris Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Angina Pectoris Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Angina Pectoris Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Angina Pectoris Drugs Market Size Growth Rate by Type (2019-2025)
1.3.2 Beta Blockers
1.3.3 Calcium Antagonists
1.3.4 Anticoagulants
1.3.5 Anti-Platelets
1.3.6 Others
1.4 Market Segment by Application
1.4.1 Global Angina Pectoris Drugs Market Share by Application (2019-2025)
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 ASCs
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Angina Pectoris Drugs Market Size
2.1.1 Global Angina Pectoris Drugs Revenue 2014-2025
2.1.2 Global Angina Pectoris Drugs Sales 2014-2025
2.2 Angina Pectoris Drugs Growth Rate by Regions
2.2.1 Global Angina Pectoris Drugs Sales by Regions 2014-2019
2.2.2 Global Angina Pectoris Drugs Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Angina Pectoris Drugs Sales by Manufacturers
3.1.1 Angina Pectoris Drugs Sales by Manufacturers 2014-2019
3.1.2 Angina Pectoris Drugs Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Angina Pectoris Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Angina Pectoris Drugs Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Angina Pectoris Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Angina Pectoris Drugs Price by Manufacturers
3.4 Key Manufacturers Angina Pectoris Drugs Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Angina Pectoris Drugs Market
3.6 Key Manufacturers Angina Pectoris Drugs Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Beta Blockers Sales and Revenue (2014-2019)
4.1.2 Calcium Antagonists Sales and Revenue (2014-2019)
4.1.3 Anticoagulants Sales and Revenue (2014-2019)
4.1.4 Anti-Platelets Sales and Revenue (2014-2019)
4.1.5 Others Sales and Revenue (2014-2019)
4.2 Global Angina Pectoris Drugs Sales Market Share by Type
4.3 Global Angina Pectoris Drugs Revenue Market Share by Type
4.4 Angina Pectoris Drugs Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Angina Pectoris Drugs Sales by Application
6 United States
6.1 United States Angina Pectoris Drugs Breakdown Data by Company
6.2 United States Angina Pectoris Drugs Breakdown Data by Type
6.3 United States Angina Pectoris Drugs Breakdown Data by Application
7 European Union
7.1 European Union Angina Pectoris Drugs Breakdown Data by Company
7.2 European Union Angina Pectoris Drugs Breakdown Data by Type
7.3 European Union Angina Pectoris Drugs Breakdown Data by Application
8 China
8.1 China Angina Pectoris Drugs Breakdown Data by Company
8.2 China Angina Pectoris Drugs Breakdown Data by Type
8.3 China Angina Pectoris Drugs Breakdown Data by Application
9 Rest of World
9.1 Rest of World Angina Pectoris Drugs Breakdown Data by Company
9.2 Rest of World Angina Pectoris Drugs Breakdown Data by Type
9.3 Rest of World Angina Pectoris Drugs Breakdown Data by Application
9.4 Rest of World Angina Pectoris Drugs Breakdown Data by Countries
9.4.1 Rest of World Angina Pectoris Drugs Sales by Countries
9.4.2 Rest of World Angina Pectoris Drugs Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.1.4 Angina Pectoris Drugs Product Introduction
10.1.5 Pfizer Recent Development
10.2 Bayer
10.2.1 Bayer Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.2.4 Angina Pectoris Drugs Product Introduction
10.2.5 Bayer Recent Development
10.3 AstraZeneca
10.3.1 AstraZeneca Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.3.4 Angina Pectoris Drugs Product Introduction
10.3.5 AstraZeneca Recent Development
10.4 Gilead
10.4.1 Gilead Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.4.4 Angina Pectoris Drugs Product Introduction
10.4.5 Gilead Recent Development
10.5 Novartis
10.5.1 Novartis Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.5.4 Angina Pectoris Drugs Product Introduction
10.5.5 Novartis Recent Development
10.6 GlaxoSmithKline
10.6.1 GlaxoSmithKline Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.6.4 Angina Pectoris Drugs Product Introduction
10.6.5 GlaxoSmithKline Recent Development
10.7 Merck
10.7.1 Merck Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.7.4 Angina Pectoris Drugs Product Introduction
10.7.5 Merck Recent Development
10.8 Mylan
10.8.1 Mylan Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.8.4 Angina Pectoris Drugs Product Introduction
10.8.5 Mylan Recent Development
10.9 Teva Pharmaceutical
10.9.1 Teva Pharmaceutical Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.9.4 Angina Pectoris Drugs Product Introduction
10.9.5 Teva Pharmaceutical Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Angina Pectoris Drugs Sales Channels
11.2.2 Angina Pectoris Drugs Distributors
11.3 Angina Pectoris Drugs Customers
12 Market Forecast
12.1 Global Angina Pectoris Drugs Sales and Revenue Forecast 2019-2025
12.2 Global Angina Pectoris Drugs Sales Forecast by Type
12.3 Global Angina Pectoris Drugs Sales Forecast by Application
12.4 Angina Pectoris Drugs Forecast by Regions
12.4.1 Global Angina Pectoris Drugs Sales Forecast by Regions 2019-2025
12.4.2 Global Angina Pectoris Drugs Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Angina Pectoris Drugs Market Size Growth Rate by Type (2019-2025)
1.3.2 Beta Blockers
1.3.3 Calcium Antagonists
1.3.4 Anticoagulants
1.3.5 Anti-Platelets
1.3.6 Others
1.4 Market Segment by Application
1.4.1 Global Angina Pectoris Drugs Market Share by Application (2019-2025)
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 ASCs
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Angina Pectoris Drugs Market Size
2.1.1 Global Angina Pectoris Drugs Revenue 2014-2025
2.1.2 Global Angina Pectoris Drugs Sales 2014-2025
2.2 Angina Pectoris Drugs Growth Rate by Regions
2.2.1 Global Angina Pectoris Drugs Sales by Regions 2014-2019
2.2.2 Global Angina Pectoris Drugs Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Angina Pectoris Drugs Sales by Manufacturers
3.1.1 Angina Pectoris Drugs Sales by Manufacturers 2014-2019
3.1.2 Angina Pectoris Drugs Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Angina Pectoris Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Angina Pectoris Drugs Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Angina Pectoris Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Angina Pectoris Drugs Price by Manufacturers
3.4 Key Manufacturers Angina Pectoris Drugs Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Angina Pectoris Drugs Market
3.6 Key Manufacturers Angina Pectoris Drugs Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Beta Blockers Sales and Revenue (2014-2019)
4.1.2 Calcium Antagonists Sales and Revenue (2014-2019)
4.1.3 Anticoagulants Sales and Revenue (2014-2019)
4.1.4 Anti-Platelets Sales and Revenue (2014-2019)
4.1.5 Others Sales and Revenue (2014-2019)
4.2 Global Angina Pectoris Drugs Sales Market Share by Type
4.3 Global Angina Pectoris Drugs Revenue Market Share by Type
4.4 Angina Pectoris Drugs Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Angina Pectoris Drugs Sales by Application
6 United States
6.1 United States Angina Pectoris Drugs Breakdown Data by Company
6.2 United States Angina Pectoris Drugs Breakdown Data by Type
6.3 United States Angina Pectoris Drugs Breakdown Data by Application
7 European Union
7.1 European Union Angina Pectoris Drugs Breakdown Data by Company
7.2 European Union Angina Pectoris Drugs Breakdown Data by Type
7.3 European Union Angina Pectoris Drugs Breakdown Data by Application
8 China
8.1 China Angina Pectoris Drugs Breakdown Data by Company
8.2 China Angina Pectoris Drugs Breakdown Data by Type
8.3 China Angina Pectoris Drugs Breakdown Data by Application
9 Rest of World
9.1 Rest of World Angina Pectoris Drugs Breakdown Data by Company
9.2 Rest of World Angina Pectoris Drugs Breakdown Data by Type
9.3 Rest of World Angina Pectoris Drugs Breakdown Data by Application
9.4 Rest of World Angina Pectoris Drugs Breakdown Data by Countries
9.4.1 Rest of World Angina Pectoris Drugs Sales by Countries
9.4.2 Rest of World Angina Pectoris Drugs Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.1.4 Angina Pectoris Drugs Product Introduction
10.1.5 Pfizer Recent Development
10.2 Bayer
10.2.1 Bayer Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.2.4 Angina Pectoris Drugs Product Introduction
10.2.5 Bayer Recent Development
10.3 AstraZeneca
10.3.1 AstraZeneca Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.3.4 Angina Pectoris Drugs Product Introduction
10.3.5 AstraZeneca Recent Development
10.4 Gilead
10.4.1 Gilead Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.4.4 Angina Pectoris Drugs Product Introduction
10.4.5 Gilead Recent Development
10.5 Novartis
10.5.1 Novartis Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.5.4 Angina Pectoris Drugs Product Introduction
10.5.5 Novartis Recent Development
10.6 GlaxoSmithKline
10.6.1 GlaxoSmithKline Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.6.4 Angina Pectoris Drugs Product Introduction
10.6.5 GlaxoSmithKline Recent Development
10.7 Merck
10.7.1 Merck Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.7.4 Angina Pectoris Drugs Product Introduction
10.7.5 Merck Recent Development
10.8 Mylan
10.8.1 Mylan Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.8.4 Angina Pectoris Drugs Product Introduction
10.8.5 Mylan Recent Development
10.9 Teva Pharmaceutical
10.9.1 Teva Pharmaceutical Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Angina Pectoris Drugs
10.9.4 Angina Pectoris Drugs Product Introduction
10.9.5 Teva Pharmaceutical Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Angina Pectoris Drugs Sales Channels
11.2.2 Angina Pectoris Drugs Distributors
11.3 Angina Pectoris Drugs Customers
12 Market Forecast
12.1 Global Angina Pectoris Drugs Sales and Revenue Forecast 2019-2025
12.2 Global Angina Pectoris Drugs Sales Forecast by Type
12.3 Global Angina Pectoris Drugs Sales Forecast by Application
12.4 Angina Pectoris Drugs Forecast by Regions
12.4.1 Global Angina Pectoris Drugs Sales Forecast by Regions 2019-2025
12.4.2 Global Angina Pectoris Drugs Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
